Zhang Fu-Qiang, Jiang Jin-Lan, Zhang Jing-Tian, Niu Han, Fu Xue-Qi, Zeng Lin-Lin
Scientific Research Centre of China-Japan Union Hospital, Jilin University, Changchun, Jilin Province, China.
School of Life Sciences, Jilin University, Changchun, Jilin Province, China.
Neural Regen Res. 2020 Feb;15(2):242-250. doi: 10.4103/1673-5374.265544.
Alzheimer's disease is a common progressive neurodegenerative disorder, pathologically characterized by the presence of β-amyloid plaques and neurofibrillary tangles. Current treatment approaches using drugs only alleviate the symptoms without curing the disease, which is a serious issue and influences the quality of life of the patients and their caregivers. In recent years, stem cell technology has provided new insights into the treatment of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. Currently, the main sources of stem cells include neural stem cells, embryonic stem cells, mesenchymal stem cells, and induced pluripotent stem cells. In this review, we discuss the pathophysiology and general treatment of Alzheimer's disease, and the current state of stem cell transplantation in the treatment of Alzheimer's disease. We also assess future challenges in the clinical application and drug development of stem cell transplantation as a treatment for Alzheimer's disease.
阿尔茨海默病是一种常见的进行性神经退行性疾病,其病理特征为存在β-淀粉样蛋白斑块和神经原纤维缠结。目前使用药物的治疗方法仅能缓解症状,无法治愈该疾病,这是一个严重问题,影响着患者及其护理人员的生活质量。近年来,干细胞技术为神经退行性疾病的治疗提供了新的思路,这些疾病包括阿尔茨海默病、帕金森病和肌萎缩侧索硬化症。目前,干细胞的主要来源包括神经干细胞、胚胎干细胞、间充质干细胞和诱导多能干细胞。在本综述中,我们讨论了阿尔茨海默病的病理生理学和一般治疗方法,以及干细胞移植治疗阿尔茨海默病的现状。我们还评估了干细胞移植作为阿尔茨海默病治疗方法在临床应用和药物开发方面未来面临的挑战。